Overall rank by patents
#24,982
of 50,000 tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 9 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (PEPTIDES).
The verdict
According to USPTO PatentsView, Peptidream ranks #24,982 of 50,000 tracked US assignees by granted-patent volume, with 11 patents across 9 technology areas.
USPTO PatentsView assignee plate
Corpus R24982 · Foreign Corporation #24,982 · 11 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: Parenteral Technologies, Llc (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Peptidream · this assignee
31 score
3D Lighting Innovati… · lowest
7 score
What this shows Peptidream's Innovation Score is 30.9/100 (top 64% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Peptidream Inc. is a focused PatentsView assignee: 9 CPC subclasses with 81.8% of grants classified under C07K (PEPTIDES). Peak complete grant year is 2020 (3 grants) versus a trough of 1 in 2017. By volume, Peptidream sits between Parenteral Technologies, Llc and Pericom Semiconductor Corporation.
Peptidream Inc. shows 2 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Parenteral Technologies, LLC
11 patents
Parker Hannifin Manufacturing Limited
11 patents
Pattern Bioscience, Inc.
11 patents
PendoTECH
11 patents
Peptilogics, Inc.
11 patents
PerceptiMed, Inc.
11 patents
Percutaneous Cardiovascular Solutions Pty Ltd
11 patents
Pericom Semiconductor Corporation
11 patents
PeptiDream Inc.
11 patents
What this shows Peptidream holds 11 patents at rank #24,991, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #24,991 in granted patent volume.
Other assignees with the most granted patents in Peptidream's primary technology class.
Peptidream's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
31 Top 64% higher than 36% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 9.1% |
| 2019 | 1 | 9.1% |
| 2020 | 3 | 27.3% |
| 2021 | 1 | 9.1% |
| 2024 | 2 | 18.2% |
| 2025partial year | 3 | 27.3% |
Top 9 of 9 technology areas
Overall rank by patents
#24,982
of 50,000 tracked assignees
30.9 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.